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Serum Cholesterol and Cognitive Performance in the Framingham Heart Study
PENELOPE K. ELIAS, PHD, MERRILL F. ELIAS, PHD, RALPH B. D’AGOSTINO, PHD, LISA M. SULLIVAN, PHD, AND
PHILIP A. WOLF, MD
Objective: The objective of this study was to examine the relationship between total cholesterol (TC) and cognitive performance
within the context of the Framingham Heart Study, a large, community-based, prospective investigation of cardiovascular risk
factors. Methods: Participants were 789 men and 1105 women from the Framingham Heart Study original cohort who were free
of dementia and stroke and who received biennial TC determinations over a 16- to 18-year surveillance period. Cognitive tests were
administered 4 to 6 years subsequent to the surveillance period and consisted of measures of learning, memory, attention/
concentration, abstract reasoning, concept formation, and organizational abilities. Statistical models were adjusted for multiple
demographic and biological covariates. Results: There was a significant positive linear association between TC and measures of
verbal fluency, attention/concentration, abstract reasoning, and a composite score measuring multiple cognitive domains. Perfor-
mance levels for three clinically defined groups were examined. Participants with “desirable” TC levels (200 mg/dL) performed
less well than participants with borderline-high TC levels (200–239 mg/dL) and participants with high TC levels (?240 mg/dL).
Conclusions: Lower naturally occurring TC levels are associated with poorer performance on cognitive measures, which place high
demands on abstract reasoning, attention/concentration, word fluency, and executive functioning. Key words: total cholesterol,
cognition, cardiovascular risk factors.
CVD  cardiovascular disease; TC  total cholesterol; MAP 
mean arterial pressure; BMI  body mass index.
INTRODUCTION
A lthough a number of risk factors for cardiovascular dis-ease (CVD) and stroke are related to lower cognitive
functioning, eg, diabetes, obesity, and hypertension (1), the
association between total serum cholesterol (TC) and cogni-
tion remains elusive. Both high and low TC have been related
to deficits in cognitive performance. For example, low levels
of TC (most frequently defined as 200 mm/dL or160
mm/dL) have been associated with mild to severe cognitive
deficit (2–6) and development of dementia (7). However, high
levels of TC (usually defined as240 mm/dL) also have been
associated with poorer cognitive test performance (8–11).
Most studies concerned with TC and cognition have used
brief tests of cognitive impairment such as the Mini-Mental
State Examination and its variants (3,5,7,12,15) or only a few
outcome measures (2). Several studies have relied on com-
posite scores from a battery of cognitive tests or clinical
evaluation of cognitive impairment (4,8–10). Because the
major concern in these investigations was with overall poor
cognition as defined by specific performance cutoffs, the
relationship of TC and cognitive functioning within specific
cognitive domains over a wide range of cognitive scores was
not explored. Furthermore, many of the studies used only
clinic samples (2,3,5,10–12) rather than community-based
populations.
A few studies of TC and cognitive performance have
involved tests designed to measure specific cognitive do-
mains. Swan et al. (13) found that, among monozygotic twin
pairs discordant for cognitive decline on the Digit Symbol
Substitution test over a period of 5 years, the twins who
declined in performance level exhibited significantly lower
TC levels at the baseline assessment relative to the twins
showing no decline. Using a choice reaction time task, Benton
(14,15) found that lower cholesterol values were associated
with slower decision and movement times. Among females,
the relationship between TC and cognitive measures was
linear. Among males, however, both low and high cholesterol
values were associated with slower decision times. Muldoon
et al. (16,17) administered cognitive tests from the Wechsler
Adult Intelligence Scale reflecting both crystallized and fluid
intelligence and found that cognitive performance decreased
with increasing levels of TC for two measures of crystallized
intelligence (information and vocabulary). For fluid intelli-
gence (block design), performance was poorest at the lowest
TC level and improved with increasing levels of TC. Finally,
recent increases in TC levels have been found to be associated
with better memory performance in healthy, middle-aged
women (18).
The present study used the Framingham Heart Study orig-
inal cohort, a large community-based sample for whom bien-
nial physical examinations for multiple CVD risk factors,
including TC, were conducted over a period of 28 years before
cognitive testing. The availability of data on concomitant
CVD risk factors and events during the surveillance period
allowed these variables to be included as covariates in statis-
tical models.
The following questions were addressed: 1) Is the relation-
ship between TC and cognitive performance positive, so that
higher TC levels are associated with better performance, or
negative, so that higher TC levels are associated with poorer
performance? 2) Are these relationships observed for multiple
cognitive abilities or are they limited to specific cognitive
domains? 3) Is the relationship between TC and cognitive
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performance modified with statistical control for concomitant
CVD risk factors?
METHODS
Subjects
The initial pool of study participants included 2123 males and females in
the Framingham Heart Study, aged 55 to 88 years, who were administered a
battery of neuropsychologic tests (19) during their 14th or 15th biennial
examination (1974–1978). All subjects had been assessed for cardiovascular
and cerebrovascular disease events and risk factors by physician examination
on a biennial schedule from 1948 to the time of neuropsychologic testing.
The surveillance window for measurement of TC extended from exami-
nations 4 through 12, and thus it preceded neuropsychologic testing by 4 to 6
years. Of the 2123 eligible participants, 229 people were excluded based on
the following criteria as determined at the time of neuropsychologic testing:
1) failure to attend examination 4 (baseline measurement, to assure that early
measures of TC and covariates were included for every participant; n  87);
2) attendance at fewer than six examinations (to assure that an adequate
sampling of TC measurements was available for every participant; n  36);
3) history of completed stroke (n  78); and 4) history of dementia (n  28).
The final sample consisted of 789 men and 1105 women.
Total Serum Cholesterol
The methods for determination of total serum cholesterol (in milligrams
per deciliter) have been described previously (20). TC determinations were
made at each examination during the surveillance period. Multiple measures
of TC are important in determining long-term TC levels because previous
studies have shown that considerable intraindividual variation over time is
common (21,22). Thus, a minimum of six and a maximum of nine measure-
ments were available for each subject. Mean TC levels were calculated by
summing the values for each examination and dividing by the number of
examinations attended.
In addition to treating mean TC values as a continuous variable in multiple
regression analyses described subsequently, the mean values were classified
into 3 clinically relevant categories: 1) 200 mg/dL, 2) 200 to 239 mg/dL,
and 3) 240 mg/dL. These TC categories are described as “desirable,”
“borderline-high,” and “high” by the National Cholesterol Education Program
Expert Panel (23). Ranges for the low and high TC categories in our sample
were 150 to 199 and 240 to 380 mg/dL, respectively. These categories were
chosen for describing the association between TC and cognitive performance
because they provide a clinical frame of reference.
Covariates
Demographic covariates included age (years), maximum education level
attained, and highest occupational level attained. The demographic covariates
were determined at the time of cognitive testing.
Additional data on concomitant CVD risk factors and TC-related variables
were used to create a set of biologic covariates. CVD risk factor variables
were calculated from data obtained during the same surveillance window used
for the determination of TC and consisted of the following: 1) mean arterial
pressure (MAP), calculated as (diastolic blood pressure  [systolic blood
pressure diastolic blood pressure]/3); 2) body mass index (BMI), calculated
as weight (kg)/height (m)2; 3) self-reported number of cigarettes smoked per
day; and 4) self-reported number of alcoholic beverages consumed per week,
converted to ounces of alcohol consumed per week. A mean score for each
variable was calculated by summing the values obtained during the surveil-
lance window and dividing by the number of examinations attended. A fifth
risk factor covariate was presence or absence of a diagnosis of type II diabetes
determined by 1) age greater than 30 years at time of diagnosis, 2) treatment
with insulin or oral hypoglycemic agents, or 3) a casual blood glucose level
8.3 mmol/L. A person was defined as diabetic if the criteria were met during
the surveillance period. Finally, a diagnosis of CVD before or concurrent with
cognitive testing constituted a sixth covariate coded as present (1) or absent
(0).
Two TC-related covariates were created based on studies indicating that
they may also have potential relationships to cognitive functioning (24–26):
self-reported use of cholesterol-lowering medication and self-reported adher-
ence to a cholesterol-lowering diet. These covariates were coded as present/
absent at the time of neuropsychologic testing and were included in the
biologic covariate model. Lastly, because many medications are known to
have cognitive side effects, medications in use at the time of cognitive testing
were grouped into three categories and coded as present/absent for each
category: cardiovascular drugs (including antihypertensive drugs, anticoagu-
lants, antiangina drugs, and so on), psychotropic drugs (including tranquiliz-
ers and sleeping aids), and a general category including all other medications.
These three additional variables were added to the biologic covariate set.
Distributional properties of the demographic and biologic covariate sets are
shown in Table 1.
Cognitive Test Battery
The cognitive test battery included eight subtests from the Wechsler Adult
Intelligence Scale, the Wechsler Memory Scale, and the Multilingual Aphasia
Examination (19). The subtests measure verbal memory and learning, visual
organization and memory, attention and concentration, abstract reasoning,
concept formation, and organizational abilities (27). Administration time for
this battery was 30 to 45 minutes and subtests were given in the following
sequence: logical memory–immediate recall, visual reproductions, paired
associates learning, digit span forward, digit span backward, word fluency
(controlled oral word associations), similarities, and logical memory–delayed
recall. Normative test data for the cognitive measures, including norms for
various age and education categories, have been published for the Framing-
ham Study participants (19).
Based on an earlier factor analysis of the cognitive test battery (19), two
composite score variables were constructed. The first composite, labeled
learning/memory, reflects learning of new verbal and visual material with an
emphasis on secondary memory processes. It consists of logical memory–
immediate recall, visual reproductions, and paired associates, all equally
weighted. The second composite, labeled attention/concentration, reflects
memory for digits (presented orally), but also attention, passive span of
apprehension, and concentration, specifically, “double-tracking,” which re-
quires simultaneous working memory and reversing operations (27). It con-
sists of digit span forward and digit span backward, again, equally weighted.
Because one primary purpose of this study was to ascertain whether TC
levels affected specific cognitive domains, we limited reporting of data to
those cognitive measures reflecting relatively independent abilities. Thus, the
set of measures relevant to our purpose consists of 1) the learning/memory
composite; 2) the attention/concentration composite; 3) similarities, a measure
of abstract reasoning and concept formation; and 4) word fluency, a measure
of executive functioning and organization. Finally, a total composite score,
representing overall cognitive performance, was constructed by summing the
4 cognitive measures. This score served as a protection scheme against
possible unreliability of individual test measures and spurious statistically
significant findings resulting from use of multiple cognitive measures.
Statistical Methods
Preliminary analyses were conducted to evaluate the relationship of the
continuous distribution of TC values to each cognitive performance measure.
For these analyses, the mean TC distribution was log-transformed (lnTC) to
normalize the distribution. Linear and quadratic lnTC terms were entered
hierarchically into two models defined by covariates. In a basic model, age,
gender, education level, and occupation level were included as demographic
covariates, along with the lnTC variable. In a biologic covariate model, the
following variables were added to the basic model: mean arterial pressure,
BMI, cigarette smoking, alcohol consumption, history of diabetes, history of
CVD, use of cholesterol-lowering drugs, adherence to a cholesterol-lowering
diet, and use of psychotropic, cardiovascular, or other drugs.
The main analyses of clinical TC categories followed the same analytic
strategy of basic and biologic covariate models as the preliminary analyses.
The three TC groups were entered into the general linear models as an ordinal
class variable (28).
Two sets of secondary analyses were conducted. First, because previous
studies presented the possibility that poorer cognition is associated with very
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high and/or low TC values, each of the “desirable” and “high” TC categories
were split into two groups, and five-group analyses were conducted using the
same models as for the three-group analyses. Although the five-group anal-
yses provide additional information about the extremes of the cholesterol
distribution as presented in our sample, they are less powerful in terms of
smaller n’s in the very high and low TC groups and are not directly applicable
to currently accepted clinical TC categories.
Second, the surveillance period was redefined as concurrent with cogni-
tive testing, thus allowing for a cross-sectional analysis of the TC–cognition
relationship at examinations 14/15. These data were subjected to the same
statistical procedures described previously.
RESULTS
In Table 1, demographic and covariate data are displayed
by TC group. The mean TC values ( standard deviation
[SD]) for each TC group were: 1) 185.0  11.0, 2) 221.2 
11.2, and 3) 272.5  26.8. Age increased from the lowest to
highest cholesterol group. The middle TC group smoked the
most cigarettes/day and consumed the most alcohol. As might
be expected, higher BMI and MAP, greater use of cardiovas-
cular and cholesterol-lowering medications, adherence to a
cholesterol-lowering diet, and higher prevalence of CVD were
all characteristic of the highest TC group.
Using the basic model described previously, a preliminary
analysis was conducted to determine if there was a significant
gender  TC interaction. The interaction term was nonsignif-
icant for all cognitive test variables (p range  0.22–0.85).
Thus, a main effects model, including gender, was used for all
subsequent analyses.
Preliminary Analyses: The Continuous Total
Cholesterol Distribution
Results were the same for the basic and biological covariate
models. The quadratic term failed to reach statistical significance
for all of the cognitive measures. The linear lnTC term was
significant for the following variables: similarities (p.03), word
fluency (p.002), attention/concentration (p.03), and the total
composite (p .02). In all analyses, lnTC was positively related
to the scores on the cognitive variables, ie, lower lnTC levels were
associated with poorer cognitive performance. The pattern of
significant results was the same when this analysis was repeated
with the untransformed TC scores.
Total Cholesterol Clinical Categories
Covariate-adjusted group means, standard errors of the
mean (SE), overall F tests of the TC variable, and results of
pairwise t tests between TC groups are shown in Table 2.
Again, results were essentially identical for the basic and
biologic risk factor models; consequently, the findings pre-
sented subsequently are for the biologic risk factor model. As
can be seen in Table 2, the low TC group performed more
poorly on similarities, word fluency, attention/concentration,
and the total composite. However, for similarities, the overall
test of significance as not statistically significant (p  .08).
The total composite scores were transformed to z-scores
(mean  0, SD  1) to meaningfully evaluate the statistical
group differences. Thus, as can be seen in the bottom row of
Table 2, the low TC group performed 0.10 SD below the mean
of the sample and 0.18 SD below the high TC group.
Although adjusted raw score differences between groups
are relatively small, the finding of poorer performance by the
low TC group is consistent with previous studies demonstrat-
ing similar results. In terms of cardiovascular risk, this group
is considered to have cholesterol levels in the “desirable”
range. To describe their cognitive risk in epidemiologic terms,
we performed logistic regression analyses with the highest TC
TABLE 1. Demographic and Covariate Information by Total Cholesterol Group for the Framingham Heart Study Sample (N  1894) Who
Participated in Cognitive Testing at Examinations 14 or 15
TC 200
(n  248)
TC 200 to 239
(n  681)
TC 240
(n  965)
p †
Mean SD* Mean SD* Mean SD*
Age (years) 63.6 6.5 66.4 7.2 69.0 7.5 0.01
Education‡ 4.8 1.6 4.8 1.6 4.7 1.7 NS
Occupation§ 4.2 1.5 4.0 1.6 4.0 1.6 NS
Cigarettes/day 7.7 10.8 9.2 11.8 6.6 9.8 0.01
Alcohol (ounces/wk) 3.6 5.5 4.3 5.4 3.7 5.4 0.04
Body mass index 25.3 4.0 25.6 3.6 26.1 3.8 0.01
Mean arterial pressure 96.2 10.2 97.3 10.4 101.0 10.8 0.01
No. Percent No. Percent No. Percent
Female 139 56.1 340 50.1 623 64.6 0.01
Diabetes 17 6.9 56 8.2 93 4.9 NS
Cardiovascular disease 26 10.5 108 15.9 222 23.0 0.01
Cholesterol-lowering diet 4 1.6 19 2.8 69 7.2 0.01
Cholesterol-lowering drugs 1 0.4 4 0.6 34 3.5 0.01
Cardiovascular drugs 65 26.2 203 29.8 409 42.4 0.01
Psychotropic drugs 21 8.5 77 11.3 102 10.6 NS
Other drugs 110 44.4 333 48.9 488 50.6 NS
*Standard deviation.
†Significance levels for overall differences among TC groups: F tests for continuous variables; chi-squared tests for categorical variables; NS  nonsignificant.
‡Education was measured on a scale of 0 to 8 in which 0 represented no years of formal schooling and 8 represented postgraduate levels.
§Occupation was measured on a scale of 1 to 7 in which 1 represented executive/professional occupations and 7 represented unskilled labor.
P. K. ELIAS et al.
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group as the referent and determined the odds ratios for the
two lower TC group relative to the highest TC group. Specif-
ically, we estimated the odds of performing in the lower 33rd
percentile (poor performance) and the lower 10th percentile
(very poor performance) of the full distribution of test scores.
The odds ratios for the middle TC group (relative to the high
TC group) were statistically nonsignificant (all p’s 0.10).
Odds ratios for the low TC group (relative to the high TC
group) are shown in Table 3.
Secondary Analyses
As described previously, the high and low TC categories
were each split into two groups, and five-group analyses,
identical to the three-group analyses, were conducted. The two
lower TC groups had mean TC levels of 171.0  6.8 and
190.8  6.0. The two higher TC groups had mean TC levels
of 263.4  16.6 and 321.5  18.3. Results of the five-group
analyses are presented in Table 4.
Like with the three-group analyses, overall significant
group differences were observed for word fluency (p .003),
the attention/concentration composite (p .02), and the total
composite (p .01). As can be seen in Table 4, the relation-
ship between TC groups and word fluency exhibits a nearly
linear trend across groups, with the lowest TC group perform-
ing most poorly and the highest TC group performing best.
The results for attention/concentration and the total composite
are characterized primarily by poorer performance in the low-
est TC group relative to the three highest groups. For the total
composite, the lowest TC group performed 0.22 SD below the
mean and 0.39 SD below the highest TC group.
When the TC surveillance window was defined as concur-
rent with cognitive testing (examinations 14/15) and the orig-
inal three-group TC analyses conducted, a similar pattern of
results was obtained, although the overall F test of differences
among TC groups was not significant for similarities and
attention/concentration. However, the results for word fluency
and the total composite were statistically significant (p’s
0.002 and 0.01, respectively), with the low TC group per-
forming more poorly than the middle and high TC groups for
both variables (p’s 0.05).
DISCUSSION
The present study used a large, prospective, community-
based sample of men and women who were free of stroke and
dementia up to the time of cognitive testing. The TC surveil-
lance period made use of an average of multiple TC determi-
nations, and thus the potential unreliability of a single mea-
surement was avoided. Extensive information regarding CVD
risk factors and events concurrent with TC measurements was
TABLE 2. Adjusted Means (z Scores) and Standard Errors of the Mean (SE) by Three Total Cholesterol (TC) Groups for the Neuropsychologic
Tests and the Total Composite Score*
Group 1 Group 2 Group 3
TC  150 to 199
(n  248)
TC  200 to 240
(n  681)
TC  240 to 380
(n  965)
Overall TC
group test
Group
contrasts
Mean SE Mean SE Mean SE p  p .05
Similarities 11.19 0.29 11.89 0.17 11.90 0.15 0.08 12,3
Word fluency 29.40 0.70 31.68 0.42 32.20 0.37 0.002 12,3
Learning/memory 8.42 0.14 8.60 0.08 8.35 0.07 NS
Attention/concentration 4.85 0.06 4.98 0.04 5.04 0.03 0.01 13
Total composite 53.92 0.94 56.90 0.56 57.36 0.50 0.01 12,3
Total composite (z scores) 0.10 0.05 0.06 0.03 0.08 0.01 0.01 12,3
*Means are adjusted for the following covariates: age, gender, education, occupation, cigarettes/day, alcohol consumption (ounces/week), body mass index, mean
arterial pressure, type II diabetes, cardiovascular disease, cardiovascular drugs, psychoactive drugs, other drugs, cholesterol-lowering drugs, and cholesterol-
lowering diet.
TABLE 3. Odds Ratios (and 95% Confidence Limits [CLs]) for Poorer Performance by Low Total Cholesterol Group (<200 mg/dL) Relative to
the High Total Cholesterol Group (>240 mg/dL)*
Performance Below the
33rd Percentile
Performance Below the
10th Percentile
Odds ratio 95% CL p  Odds ratio 95% CL p 
Similarities 1.46 1.00–2.12 .06 2.17 1.22–3.87 .01
Word fluency 1.76 1.25–2.49 .002 1.84 1.09–3.08 .02
Attention/concentration 1.45 1.01–2.10 .06 2.24 1.38–3.61 .004
Total composite 1.49 1.02–2.18 .03 1.80 1.01–3.18 .03
*Odds ratios are adjusted for the following covariates: age, gender, education, occupation, cigarettes/day, alcohol consumption (ounces/week), body mass index,
mean arterial pressure, type II diabetes, cardiovascular disease, cardiovascular drugs, psychoactive drugs, other drugs, cholesterol-lowering drugs, and
cholesterol-lowering diet.
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available, allowing for statistical adjustment for these factors
in multivariable models.
The large sample size used in this study is a strength, but it
is particularly important to determine whether the relations
between TC and cognitive performance are important as well
as statistically significant. Adjusted for multiple demographic
and cardiovascular risk factors, the difference between means
for the lowest TC group and the highest TC group for the total
composite score, expressed in Z scores (units of SD) was 0.39
(Table 4). This relationship might not be considered important
in clinical practice. However, with regard to the population as
a whole, a relationship of this size is very likely significant in
epidemiologic (population) terms as is indicated by the in-
crease in risk for poor performance expressed by the odds
ratios shown in Table 3.
Consistent with studies demonstrating poorer cognitive
performance for lower TC levels, we found that earlier low TC
levels were predictive of poorer performance for similarities,
word fluency, attention/concentration, and overall cognitive
performance, as measured by the total composite. This was
especially evident among people with TC levels lower than
180 mg/dL. Similar results were shown when TC was mea-
sured at the time of cognitive testing, although findings for
attention/concentration and similarities were no longer signif-
icant. It should be noted that the effects of longitudinally
measured TC on these specific cognitive measures were gen-
erally small in terms of raw score differences (see Table 2),
and the lack of significant episodic findings may be related to
the unreliability of the single available TC measurement
(21,22), thus reducing the probability of detecting small dif-
ferences.
Two of the cognitive variables most strongly associated
with TC, ie, the attention/concentration composite and word
fluency, place demands on executive functioning processes
(29,30). In this regard, it is important to note that tests mea-
suring speed of mental processing (3–15) and fluid intelli-
gence (16,17) have shown positive linear relationships with
TC in previous studies. Executive abilities and speed of men-
tal processing have been shown to account for a significant
amount of the variance in fluid intelligence among cognitively
normal adults (31). Consequently, demands on executive
functioning may be one common feature of cognitive outcome
measures for which low TC is related to poorer performance.
The adverse effects of low TC on cognitive performance
have been reported in previous studies (13–17), and these
effects have biologic plausibility. Low cholesterol levels may
accompany chronic diseases, poor intake or absorption of
nutrients, and diagnosed and occult malignancies (32), which
in turn may be associated with poorer cognitive performance.
Low serum cholesterol and poorer cognitive functioning may
be related because neuronal cells require TC for normal met-
abolic processes (16). Furthermore, the interaction between
plasma cholesterol concentrations, cholesterol present in cell
membranes, and serotonergic activity is complex and may
account for the negative cognitive effects of low TC (33).
Although the “cholesterol–serotonin” hypothesis has been ad-
vanced to explain the associations among low TC, violent
behavior, and suicide (33), it is possible that adverse modu-
lating effects of low TC on serotonergic activity may extend to
the role of serotonin in cognitive processes as well (34).
Findings in this study are inconsistent with the set of
previous studies finding a negative association between TC
and cognitive performance (9–12). However, the lack of con-
sistency between the present findings and those studies report-
ing a high TC–poor performance relationship may be the
result of differences in methodology. The present study used
the mean of biennial TC measurements obtained over a period
of 16 to 18 years and multiple demographic and cardiovascu-
lar risk factor control variables. Thus, it was possible to
achieve greater statistical control for those risk factors com-
monly associated with high TC levels, eg, obesity and/or
higher blood pressures, both of which have been found to be
predictive of poorer cognitive function (35). Finally, it should
be noted the nonsignificant results for our learning/memory
composite are consistent with Teunissen et al. (36) who found
no baseline or longitudinal relations between TC and perfor-
TABLE 4 . Adjusted Means (z Scores) and Standard Errors of the Mean (SE) by Five Total Cholesterol (TC) Groups for the Neuropsychologic
Tests and the Total Composite Score*
Group 1 Group 2 Group 3 Group 4 Group 5
TC  150 to 179
(n  72)
TC  180 to 199
(n  176)
TC  200 to 239
(n  681)
TC  240 to 299
(n  819)
TC  300 to 380
(n  146)
Group
contrasts
Mean SE Mean SE Mean SE Mean SE Mean SE p .05
Similarities 11.41 0.52 11.09 0.35 11.88 0.17 11.85 0.16 12.21 0.39 NS
Word fluency 28.42 1.26 29.80 0.83 31.66 0.42 31.98 0.39 33.71 0.94 1,23,4,5
35
Learning/memory 8.15 0.25 8.53 0.17 8.60 0.08 8.35 0.08 8.38 0.19 NS
Attention/concentration 4.70 0.12 4.91 0.07 4.98 0.04 5.03 0.04 5.15 0.09 13,4,5 25
Total composite 51.82 1.70 54.75 1.12 56.89 0.56 57.12 0.53 59.06 1.29 13,4,5 25
Total Composite (z scores) 0.22 0.09 0.06 0.06 0.06 0.03 0.07 0.03 0.17 0.07 13,4,5 25
*Means are adjusted for the following covariates: age, gender, education, occupation, cigarettes/day, alcohol consumption (ounces/week), body mass index, mean
arterial pressure, type II diabetes, cardiovascular disease, cardiovascular drugs, psychoactive drugs, other drugs, cholesterol-lowering drugs, and cholesterol-
lowering diet.
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mance on the Auditory Verbal Learning Test, which includes
a memory component.
It is important to note that treatment for high TC was not
common or particularly effective during the period of this
study, at least by standards achieved today. None of our
participants were being treated with currently popular and
highly effective regimens for lowering cholesterol. Further-
more, the prevalence of any cholesterol treatment was low,
and we adjusted for anticholesterol drug treatment and diet.
Thus, our data do not address the consequences of reducing
TC to “desirable” levels by statins or other new cholesterol-
lowering medications. Naturally low cholesterol and choles-
terol levels lowered by successful treatment may have very
different implications for cognitive functioning. Moreover,
competing risks must always be taken into consideration.
Lower cholesterol values may have modestly detrimental ef-
fects on cognitive function for the individual but, depending
on the patient’s risk profile, may have beneficial effects with
respect to cardiovascular morbidity and mortality.
Study Limitations
This study did not include longitudinal assessment of cog-
nitive performance. The lack of baseline cognitive measures
prevented an evaluation of whether initial cognitive differ-
ences associated with TC levels are the actual determinant of
cognitive performance outcomes at examinations 14/15. Thus,
we cannot eliminate the possibility that early TC levels were
related to change in performance over time or that low TC was
actually associated with poorer performance at a younger age.
Similarly, we cannot specify a causal relationship between TC
levels and cognitive performance.
Total cholesterol may be a marker for specific biologic (eg,
serotonin, APOE genotype (16,37)) and/or psychologic (eg,
type A behavior, depression) variables, which themselves are
directly related to cognitive outcomes, but which were not
included in the present study. However, with regard to the
influence of psychologic variables on cognition in the Fra-
mingham Study cohort, Haynes et al. (38) found that very few
personality or psychosocial traits were concurrently related to
serum cholesterol levels at examinations 8/9. From among 20
psychosocial variables assessed, several significant associa-
tions were found, but primarily within specific subgroups.
Thus, it is unlikely that psychosocial variables commonly
associated with CVD risk would account for our findings.
The psychosocial scales used by Haynes et al. (38) did not
include any measures of depression, nor did the present study.
Low TC has been associated with depressed mood and clinical
depression (39,40), although not all studies report this rela-
tionship (41–43). Nonetheless, depression has been linked to
both dementia and cognitive decline (44), including poorer
performance on tasks requiring executive functioning and
verbal and nonverbal memory (45). It is possible that early
measures of depression may be associated with later cognitive
performance, and it is even more likely that this would be true
of persistent, long-term depression. Clearly, further studies are
needed to evaluate the relationships among TC, depression,
and cognition.
CONCLUSIONS
Low concentrations of naturally occurring total serum cho-
lesterol, including those levels in the currently defined “de-
sirable” range, were associated with poorer cognitive perfor-
mance, especially for those tests that place strong demands on
executive function and an overall measure of cognitive per-
formance. Hopefully, the present study will stimulate further
research designed to elucidate the mechanisms underlying
relationships between naturally lower cholesterol and lowered
cognitive functioning.
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